Refers to agonists of Fibroblast Growth Factor receptor-1 (FGFR1), that is: H1 - HVR) comprising SEQ ID no: 7, 8,9, among others (b) H2 HVR comprising SEQ ID no: 10, 12, 13, among others (c) HVR - H3 comprising SEQ ID no: 16, 17, 18, among others d) - L1 which comprises HVR Q id no: 21 e) HVR - L2 comprising SEQ ID no: 22 (f) HVR - L3 comprising SEQ ID no: 23.It also relates to a Pharmaceutical composition, being useful in the treatment of polycystic ovary syndrome, diabetes, among others.SE REFIERE A AGONISTAS DEL RECEPTOR 1 DEL FACTOR DE CRECIMIENTO FIBROBLASTICO (FGFR1), QUE TIENE: a) HVR-H1 QUE COMPRENDE SEQ ID NO:7, 8,9, ENTRE OTROS b) HVR-H2 QUE COMPRENDE SEQ ID NO: 10, 12, 13, ENTRE OTROS c) HVR-H3 QUE COMPRENDE SEQ ID NO: 16, 17, 18, ENTRE OTROS d) HVR-L1 QUE COMPRENDE SEQ ID NO: 21 e) HVR-L2 QUE COMPRENDE SEQ ID NO: 22 f) HVR-L3 QUE COMPRENDE SEQ ID NO: 23. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA, SIENDO UTIL EN EL TRATAMIENTO DEL SINDROME DE OVARIO POLIQUISTICO, DIABETES, ENTRE OTRAS.
